

DISC1 and Its Protein Interactomes for Mental Function

Akira Sawa

Advances in psychiatric genetics in the past decade have been amazing. The team effort at the global level has provided an invaluable encyclopedia. Furthermore, this information may be useful in identifying biomarkers and stratifying patients. Thus, its clinical utility may be high in the coming years. Nevertheless, it is unclear how much such rich information has contributed to a mechanistic understanding of disease pathophysiology. One concern is that the effect size of almost all genes identified by genome-wide association studies may be too small to generate model animals in an effective manner.

In research for neurological disorders, such as Alzheimer's disease and Parkinson's disease, in which biological and mechanistic dissection have been made successfully, variants found in rare familial cases have been used effectively. In parallel, investigators have examined tissues from patients and identified biological changes associated with the pathophysiology, such as aberrant phosphorylation of tau protein in patients with Alzheimer's disease. Key mediators in the disease pathophysiology may not necessarily be discovered through genetic studies. Together, successful research accomplishment in biology for neurological disorders may guide the future direction of biological psychiatry by looking beyond only genetic studies to identify key proteins and pathways that mediate the pathophysiology of psychiatric phenotypes. In short, well-balanced perspectives between genetic and nongenetic approaches may be productive for the future direction.

DISC1: No More Disrupted in Schizophrenia. *DISC1* was first reported under the name "disrupted in schizophrenia" in a Scottish pedigree in which patients with major mental illnesses such as mood and psychotic disorders are extremely enriched (1). It is unclear why this gene was named *DISC1*, as the breakpoint of the balanced chromosomal translocation where the gene is disrupted was linked to several major mental illnesses, not specifically to schizophrenia. This initial report should be highly appreciated as a pioneering effort that brought molecular biology to psychiatry. Nevertheless, because of technical reasons in human genetics, Sullivan (2) noted that there is still some level of uncertainty whether we can solely attribute the occurrence of major mental illnesses to the disruption of the *DISC1* "gene." Furthermore, at least when we stand on the DSM-based categorical approach, we fail to observe a positive association between schizophrenia and the *DISC1* "genetic" locus (2).

In contrast, neurobiology built on a working hypothesis that the *DISC1* "protein" may play a key role in the processes in a wide range of major mental illnesses has been productive (3). In this context, genetically engineered models for *DISC1* have

been used not to test the pathogenic or constructive validity of the gene for specific mental illness, such as schizophrenia; instead, they are used to validate how the *DISC1* protein contributes to the biological processes or disease pathophysiology underlying major mental illnesses and neurodevelopmental disorders (4). Thus, biological study of *DISC1* for mental illnesses, not specifically for schizophrenia, is well justified in analogy to successful precedence in biological study of tau for various neurodegenerative disorders.

DISC1 Protein in Major Mental Illnesses and Neurodevelopmental Disorders. The justification of studying *DISC1* in biological psychiatry can stand on its implication at the protein level. Molecular implication in the protein context implies not only the level of the protein but also the post-translational modifications (e.g., phosphorylation, ubiquitination, and SUMOylation) and interaction with other proteins, called the protein interactome. Recent studies have reported the stability of *DISC1* protein in conjunction with ubiquitination and interaction with other proteins (5,6). The regulatory mechanisms for *DISC1* protein stability seem to be perturbed in pathological conditions, such as hypoxia (5), suggesting that this line of study is significant in the research of brain disorders. Phosphorylation of *DISC1* at a specific amino acid residue plays a fundamental regulatory role in cortical development that may underlie key behavioral constructs associated with neurodevelopmental conditions (7). A comprehensive assessment of protein interactomes involving *DISC1* was initially pioneered more than a decade ago by Camargo *et al.* (8). On the basis of such a fruitful history of research on the *DISC1* protein, the article by Wilkinson *et al.* (9) in this issue of *Biological Psychiatry* addresses *DISC1* protein interactomes in a cell type-specific manner by combining the cutting-edge technologies of human stem cell and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 genetic engineering.

Cell Type-Specific DISC1 Interactomes: Its Implication in Biological Psychiatry. *DISC1* protein is expressed not only in neurons but also in astrocytes and other glial cells (3). Although most studies on *DISC1* thus far have been made in the context of neurons and progenitors, a number of studies have explored the role of *DISC1* protein in nonneuronal cells, such as astrocytes. For example, astrocytic *DISC1* but not neuronal *DISC1* is involved in the negative impact of exposure to a cannabis constituent (Δ^9 -tetrahydrocannabinol) during adolescence on recognition memory in adulthood in a cell type-specific fashion (10). Thus, addressing cell type-specific *DISC1* protein interactomes may be the first step of addressing the biological mechanisms.

SEE CORRESPONDING ARTICLE ON PAGE 305

Wilkinson *et al.* (9) inserted a 3X-FLAG coding sequence at the C-terminal end of the endogenous *DISC1* gene using CRISPR/Cas9 genome engineering in human induced pluripotent stem cells that differentiated into neural progenitors and astrocytes, respectively. Endogenous *DISC1* binding partners were determined by immunoprecipitation of *DISC1*-FLAG followed by high-pressure liquid chromatography coupled to tandem mass spectrometry in cell type-specific settings. Wilkinson *et al.* (9) clustered three types of *DISC1* protein interactors: those common to both cell types, those that are neural progenitor specific, and those that are astrocyte specific. Importantly, in the *DISC1* interactome in neural progenitors, a significant enrichment of de novo nonsynonymous mutations in patients with schizophrenia and a suggestive enrichment of the mutations in patients with intellectual disability were observed when compared with control subjects. In summary, Wilkinson *et al.* (9) provide an example of how complementary knowledge of neurobiology and psychiatric genetics is fruitfully integrated to provide a mechanistic insight for major mental illnesses and neurodevelopmental disorders.

Significance in Studying *DISC1* Protein in Biological Psychiatry: Future Perspectives. *DISC1* protein serves as a critical hub to regulate multiple proteins, like a conductor of a symphony orchestra (3). Any conductor by her/himself is silent in generating individual sound, like the *DISC1* gene with no significant signals in most of genetic studies. Minor tuning problems with each member of the orchestra (e.g., a mutation with a modest effect size in each gene) may not result in a prominent issue by itself. However, at the level of overall functional coordination, the failure of the conductor in dealing with individual tuning problems, even if each problem is minor, may lead to a devastating outcome. Likewise, the deficits of *DISC1* protein and its interactomes play a fundamental role in the pathophysiology of major mental illnesses.

Based on this conceptual framework, what will be near-future perspectives in research of biological psychiatry when we appreciatively use *DISC1* protein as a molecular lead? First, we need to learn how the *DISC1* protein coordinates the overall function of its interactome when multiple genetic variations impact the interactors at the mechanistic levels. Second, it is crucial to know how disease-relevant environmental stressors may influence posttranslational modifications of *DISC1*, such as phosphorylation, ubiquitination, and oxidation. Accordingly, *DISC1* may mechanistically serve as a hub of gene and environmental interactions. Third, because protein interactomes include cell type-specific nature as featured here (9), the knowledge will help understand the disease mechanisms from a neuron-glia interaction viewpoint.

In conclusion, whom do you care for more: Leonard Bernstein, or each individual player in the New York Philharmonic? Probably both, which may be my answer. However, some may say, "I love Lenny."

Acknowledgments and Disclosures

This work was supported by National Institute of Mental Health Grant Nos. MH094268, MH092443, MH105660, and MH107730, and from the Stanley Foundation and the S&R/RUSK Foundation.

I thank Yukiko Lema for her assistance in manuscript preparation and Lindsay Hayes, Brian Lee, and Mikhail Pletnikov for reading and commenting on the manuscript.

The author reports no biomedical financial interests or potential conflicts of interest.

Article Information

From the Departments of Psychiatry, Neuroscience, Mental Health, and Biomedical Engineering, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, Maryland.

Address correspondence to Akira Sawa, M.D., Ph.D., Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Departments of Psychiatry, Neuroscience, Mental Health, and Biomedical Engineering, 600 N Wolfe St, Baltimore, MD 21287; E-mail: asawa1@jhmi.edu.

Received Dec 4, 2018; revised and accepted Dec 13, 2018.

References

1. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, *et al.* (2000): Disruption of two novel genes by a translocation co-segregating with schizophrenia. *Hum Mol Genet* 9:1415–1423.
2. Sullivan PF (2013): Questions about *DISC1* as a genetic risk factor for schizophrenia. *Mol Psychiatry* 18:1050–1052.
3. Brandon NJ, Sawa A (2011): Linking neurodevelopmental and synaptic theories of mental illness through *DISC1*. *Nat Rev Neurosci* 12:707–722.
4. Niwa M, Cash-Padgett T, Kubo KI, Saito A, Ishii K, Sumitomo A, *et al.* (2016): *DISC1* a key molecular lead in psychiatry and neurodevelopment: No-more Disrupted-in-Schizophrenia 1. *Mol Psychiatry* 21:1488–1489.
5. Barodia SK, Park SK, Ishizuka K, Sawa A, Kamiya A (2015): Half-life of *DISC1* protein and its pathological significance under hypoxia stress. *Neurosci Res* 97:1–6.
6. Yalla K, Elliott C, Day JP, Findlay J, Barratt S, Hughes ZA, *et al.* (2018): *FBXW7* regulates *DISC1* stability via the ubiquitin-proteasome system. *Mol Psychiatry* 23:1278–1286.
7. Ishizuka K, Kamiya A, Oh EC, Kanki H, Seshadri S, Robinson JF, *et al.* (2011): *DISC1*-dependent switch from progenitor proliferation to migration in the developing cortex. *Nature* 473:92–96.
8. Camargo LM, Collura V, Rain JC, Mizuguchi K, Hermjakob H, Kerrien S, *et al.* (2007): Disrupted in Schizophrenia 1 interactome: Evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. *Mol Psychiatry* 12:74–86.
9. Wilkinson B, Evgrafov OV, Zheng D, Hartel N, Knowles JA, Graham NA, *et al.* (2019): Endogenous cell type-specific Disrupted in Schizophrenia 1 interactomes reveal protein networks associated with neurodevelopmental disorders. *Biol Psychiatry* 85:305–316.
10. Jouroukhin Y, Zhu X, Shevelkin AV, Hasegawa Y, Abazyan B, Saito A, *et al.* (2018): Adolescent Δ^9 -tetrahydrocannabinol exposure and astrocyte-specific genetic vulnerability converge on nuclear factor-kappaB-cyclooxygenase-2 signaling to impair memory in adulthood [published online ahead of print Aug 16]. *Biol Psychiatry*.